The Pennant Group (PNTG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Executive summary
Annual meeting scheduled for May 14, 2026, with voting on three key proposals: election of directors, ratification of Deloitte & Touche LLP as auditor, and advisory approval of executive compensation.
Only shareholders of record as of March 17, 2026, are eligible to vote, with 34,953,297 shares outstanding.
Proxy materials and the 2025 Annual Report are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class I directors for three-year terms, ratifying Deloitte & Touche LLP as auditor for 2026, and approving executive compensation on an advisory basis.
Board recommends voting FOR all proposals.
Quorum requires a majority of outstanding shares; abstentions and broker non-votes count toward quorum but not as votes for proposals.
Shareholder proposals for the 2027 meeting must be submitted between February 13 and March 15, 2027.
Board of directors and corporate governance
Board is classified into three staggered classes, with annual elections for one class.
Current nominees: Christopher R. Christensen, Brent J. Guerisoli, and John G. Nackel, Ph.D.; Christensen and Nackel are independent.
Majority of board members are independent per Nasdaq rules; independent directors meet in executive session annually.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Quality Assurance and Compliance.
Board leadership combines CEO and Chairman roles, with a lead independent director.
Directors receive cash and stock compensation, with annual retainers and automatic restricted stock grants; compensation is benchmarked to peer companies.
Latest events from The Pennant Group
- Q2 revenue up 35.8% to $298M, with guidance raised on strong growth and acquisitions.PNTG
Q2 2026 - Acquisitions, quality focus, and leadership development fueled growth and margin gains in 2025.PNTG
Stephens Annual Investment Conference - Moratorium impact limited; strong growth in Home Health and Senior Living continues.PNTG
RBC Capital Markets Global Healthcare Conference 2026 - Q1 2026 revenue rose 36% to $285.4M, with strong segment growth and margin expansion.PNTG
Q1 2026 - Major acquisitions fuel growth, with integration and margin expansion as top priorities.PNTG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Record 2025 revenue and EPS growth, with 2026 guidance projecting further double-digit gains.PNTG
Q4 2025 - Expanding in the Southeast, leveraging local leadership, and preparing for regulatory changes.PNTG
Jefferies 2025 Healthcare Services Conference - Q3 revenue up 28.9% to $180.7M, adjusted EPS $0.26, and guidance raised for 2024.PNTG
Q3 2024 - Q2 revenue up 27.6%, net income doubled, and guidance raised on strong segment growth.PNTG
Q2 2024